Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF).~* Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.~* Confirmed diagnosis of CF and homozygous for the F508del-CFTR mutation~* Forced Expiratory Volume in one second/forced vital capacity (FEV1) ≥40% of predicted normal for age, sex, and height~Exclusion Criteria:~* Presence of moderate or severe hepatic impairment (Child-Pugh Class B or C)~* Subjects currently receiving invasive mechanical ventilation~* Known history of alcohol or drug abuse in the past year~* Clinically significant abnormal laboratory values during screening~* Pregnant or nursing females~* Female subjects and female partners of male subjects who plan to become pregnant during Treatment Period or within 90 days following the last dose of study drug~* History of solid organ or hematological transplantation~* Ongoing or prior participation in an investigational drug study within 30 days of screening~* Current use of commercial LUM/IVA combination therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: activated smart device alerts and feedback (Type: EXPERIMENTAL): LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
- Arm B: de-activated smart device alerts/feedback features (Type: EXPERIMENTAL): LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).